Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus tislelizumab and chemotherapy in advanced non-small cell lung cancer
ChiCTR2200066771Phase 4Not yet recruiting
- Sponsor
- Yiyang Central Hospital
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tislelizumab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Yiyang Central Hospital. Primary endpoint: Objective response rate. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200066771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066771.